Creative Planning Sorrento Therapeutics, Inc. Transaction History

Creative Planning

$93.6 Billion
Q2 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.74 - $1.83 $977 - $2,417	-1,321 Reduced 2.51%	51,362 $45,000
Q3 2022 Nov 03, 2022	BUY	$1.51 - $2.88 $8,101 - $15,451	5,365 Added 11.34%	52,683 $83,000
Q2 2022 Aug 15, 2022	BUY	$1.24 - $2.33 $11,011 - $20,690	8,880 Added 23.1%	47,318 $95,000
Q1 2022 May 16, 2022	BUY	$2.0 - $4.9 $76,876 - $188,346	38,438 New	38,438 $90,000
Q4 2021 Feb 11, 2022	SELL	$4.65 - $7.23 $71,809 - $111,652	-15,443 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$7.41 - $10.99 $53,804 - $79,798	-7,261 Reduced 31.98%	15,443 $118,000
Q2 2021 Aug 04, 2021	SELL	$6.35 - $10.0 $329,399 - $518,740	-51,874 Reduced 69.56%	22,704 $220,000
Q1 2021 Apr 30, 2021	SELL	$7.03 - $16.51 $40,788 - $95,791	-5,802 Reduced 7.22%	74,578 $617,000
Q4 2020 Jan 29, 2021	BUY	$5.76 - $11.95 $108,074 - $224,217	18,763 Added 30.45%	80,380 $549,000
Q3 2020 Nov 05, 2020	BUY	$6.17 - $18.82 $88,798 - $270,857	14,392 Added 30.48%	61,617 $687,000
Q2 2020 Jul 23, 2020	BUY	$1.73 - $6.76 $64,174 - $250,762	37,095 Added 366.19%	47,225 $297,000
Q1 2020 May 05, 2020	BUY	$1.57 - $4.76 $15,904 - $48,218	10,130 New	10,130 $19,000
Q1 2019 Apr 24, 2019	SELL	$1.86 - $5.94 $29,760 - $95,040	-16,000 Closed	0 $0
Q2 2018 Jul 20, 2018	SELL	$4.75 - $8.0 $20,662 - $34,800	-4,350 Reduced 21.38%	16,000 $115,000
Q1 2018 Apr 18, 2018	BUY	$4.5 - $9.95 $12,375 - $27,362	2,750 Added 15.63%	20,350 $105,000
Q4 2017 Jan 17, 2018	SELL	$1.75 - $3.8 $14,003 - $30,407	-8,002 Reduced 31.26%	17,600 $67,000
Q3 2017 Oct 17, 2017	BUY	$1.63 - $2.0 $41,731 - $51,204	25,602	25,602 $44,000

Others Institutions Holding SRNE

# of Institutions

Shares Held

5.48M

Call Options Held

Put Options Held

View Full List

About Sorrento Therapeutics, Inc.

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

More about SRNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Account